Article Text

PDF
Topical chemotherapy for ocular surface squamous neoplasia: current status
  1. Ricardo Sepulveda1,
  2. Jacob Pe'er2,
  3. Edoardo Midena3,
  4. Stefan Seregard4,
  5. Harminder S Dua5,
  6. Arun D Singh1
  1. 1Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA
  2. 2Department of Ophthalmology, Hadassah University Hospital Jerusalem, Israel
  3. 3Department of Ophthalmology, University of Padua, Padua, Italy
  4. 4St Erik's Eye Hospital Karolinksa University, Stockholm, Sweden
  5. 5Division of Ophthalmology and Visual Sciences, University of Nottingham, Nottingham, UK
  1. Correspondence to Dr Arun D Singh, Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA; singha{at}ccf.org

Abstract

Although there are no randomised trials directly comparing topical chemotherapeutic agents mitomycin-C, 5-fluorouracil, and interferon-α2b, published studies indicate equal efficacy of these agents for treatment of non-invasive ocular surface squamous neoplasia (80%–88%). 5-Fluorouracil may be preferred, given low incidence of serious side effects and low cost to the patient.

  • Ocular surface

Statistics from Altmetric.com

Footnotes

  • Linked articles 153197.

  • Competing interests None.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles